HitGen Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 546

Employees

  • Stock Symbol
  • 688222

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $3.88
  • (As of Friday Closing)

HitGen General Information

Description

HitGen Inc is dedicated to building a world-class biopharmaceutical enterprise. Its mission is to advance human health and quality of life. It provides therapeutic solutions to address unmet medical needs. Centered on its internationally DEL (DNA-encoded Library) technology, the Company has expanded into Fragment-Based Drug Discovery and Structure-Based Drug Design and a suite of complementary platforms based on Oligonucleotide-based Therapeutics, Targeted Proximity Drugs, and Cyclic Peptidomimetics. The group has developed HAILO, a proprietary "DEL+AI+Automation" molecular optimization platform, thereby establishing a distinctive novel molecule discovery engine that delivers both therapeutic molecules and tool molecules to the world-wide pharmaceutical industry.

Contact Information

Website
www.hitgen.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Building C2, NO.8, Huigu 1st East Road
  • Tianfu International Bio-Town, Shuangliu District
  • Chengdu, Sichuan 610200
  • China
+86 028
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • Building C2, NO.8, Huigu 1st East Road
  • Tianfu International Bio-Town, Shuangliu District
  • Chengdu, Sichuan 610200
  • China
+86 028

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HitGen Stock Performance

As of 20-Nov-2026, HitGen’s stock price is $3.88. Its current market cap is $1.56B with 401M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.88 $3.99 $3.02 - $7.10 $1.56B 401M 23.1M $0.06

HitGen Financials Summary

As of 30-Sep-2026, HitGen has a trailing 12-month revenue of $102M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,575,913 1,235,614 581,310 753,791
Revenue 102,392 73,084 59,507 52,485
EBITDA 22,950 22,251 14,492 11,839
Net Income 22,640 15,227 7,157 5,755
Total Assets 333,994 279,374 240,615 243,992
Total Debt 63,954 33,481 29,309 32,869
Public Fundamental Data provided by Morningstar, Inc. disclaimer

HitGen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore HitGen‘s full profile, request access.

Request a free trial

HitGen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore HitGen‘s full profile, request access.

Request a free trial

HitGen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
HitGen Inc is dedicated to building a world-class biopharmaceutical enterprise. Its mission is to advance human health a
Discovery Tools (Healthcare)
Chengdu, China
546 As of 2025

Millbrae, CA
 

Fremont, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

HitGen Competitors (44)

One of HitGen’s 44 competitors is Eikon Therapeutics, a Formerly VC-backed company based in Millbrae, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Eikon Therapeutics Formerly VC-backed Millbrae, CA
Eurofins DiscoverX Products Formerly VC-backed Fremont, CA
Genesis Molecular AI Venture Capital-Backed San Mateo, CA
Miltenyi Biotec Private Debt Financed Bergisch Gladbach, Germany
Horizon Discovery Formerly VC-backed Cambridge, United Kingdom
You’re viewing 5 of 44 competitors. Get the full list »

HitGen Patents

HitGen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026145630-A1 Spiro compound and use thereof Pending 31-Dec-2024
WO-2026145632-A1 Spirocyclic compound and use thereof Pending 31-Dec-2024
US-20260176303-A1 Blocking peptides and related methods, formulations, and compositions Pending 25-Dec-2024
EP-4821919-A1 Modified nucleotide monomer and use thereof Pending 08-Jan-2024
WO-2025148770-A1 Modified nucleotide monomer and use thereof Inactive 08-Jan-2024 C07D233/90
To view HitGen’s complete patent history, request access »

HitGen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HitGen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore HitGen‘s full profile, request access.

Request a free trial

HitGen Investments & Acquisitions (5)

HitGen’s most recent deal was a Early Stage VC with Connexus Therapeutics. The deal was made on 17-Sep-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Connexus Therapeutics 17-Sep-2026 Early Stage VC Drug Discovery
Leaderna Therapeutics 13-Mar-2026 Early Stage VC Drug Discovery
CrystalO Biopharma 07-Jan-2022 Early Stage VC Drug Discovery
Vernalis 02-Dec-2020 Merger/Acquisition Biotechnology
NetVation 31-Dec-2018 Merger/Acquisition Drug Discovery
To view HitGen’s complete investments and acquisitions history, request access »

HitGen ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view HitGen’s complete esg history, request access »

HitGen Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
NetVation Chengdu, China 2017
Vernalis Cambridge, United Kingdom 1986

HitGen FAQs

  • When was HitGen founded?

    HitGen was founded in 2012.

  • Where is HitGen headquartered?

    HitGen is headquartered in Chengdu, China.

  • What is the size of HitGen?

    HitGen has 546 total employees.

  • What industry is HitGen in?

    HitGen’s primary industry is Discovery Tools (Healthcare).

  • Is HitGen a private or public company?

    HitGen is a Public company.

  • What is HitGen’s stock symbol?

    The ticker symbol for HitGen is 688222.

  • What is the current stock price of HitGen?

    As of 20-Nov-2026 the stock price of HitGen is $3.88.

  • What is the current market cap of HitGen?

    The current market capitalization of HitGen is $1.56B.

  • What is HitGen’s current revenue?

    The trailing twelve month revenue for HitGen is $102M.

  • Who are HitGen’s competitors?

    Eikon Therapeutics, Eurofins DiscoverX Products, Genesis Molecular AI, Miltenyi Biotec, and Horizon Discovery are some of the 44 competitors of HitGen.

  • What is HitGen’s annual earnings per share (EPS)?

    HitGen’s EPS for 12 months was $0.06.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process